Sydney Jennings

Emergency medicine physician Kabiul Haque, MD, discusses USPSTF screening guidelines for abdominal aortic aneurysm.

Kabiul Haque, MD, a family medicine physician, shares his four-pillar approach to preventing PAD progression.

New research reveals GLP-1 receptor agonists may alter PET-CT scan interpretations, highlighting the need for updated guidelines in oncological imaging.

A family medicine physician details how to differentiate upper airway cough syndrome from asthma and GERD using clinical history and associated symptoms.

Upper airway cough syndrome is the main cause of chronic cough. A family medicine physician shares the clinical red flags that should make you suspect UACS in your primary care patients.

Discover essential insights and innovative strategies at FMX 2025, featuring key topics like AI in healthcare and advancements in family medicine.

FMX 2025: A family medicine clinician discusses the clinical significance of acute, subacute, and chronic cough timeframes and their differential diagnoses.

Sarah C. Nosal, MD, FAAFP, takes the helm as AAFP President, emphasizing community-focused family medicine and innovative healthcare solutions.

Get a first look at can’t-miss sessions from day 2 of FMX 2025—from vaccines and metabolic health to dementia, women’s care, and AI in family medicine.

From vaccines to reproductive health to AI, here are 16 sessions you won't want to miss at FMX 2025.

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.

Preview the top sessions at the AAFP Family Medicine Experience (FMX) 2025. From vaccines and obesity care to dementia and LGBTQ+ health, here are 10 highlights for family physicians.

The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

Your daily dose of the clinical news you may have missed.

Review FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for UTIs, acute pain, migraine, diabetes, and more.

Novo Nordisk aims to revolutionize diabetes care with its resubmission for insulin icodec, a potential first once-weekly basal insulin for type 2 diabetes therapy in adults.

Your daily dose of the clinical news you may have missed.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

The approval is based on phase 3 trials showing durable IGF-1 control, symptom relief, and a favorable safety profile among adults with acromegaly.

Your daily dose of the clinical news you may have missed.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

The CDC said clinicians should be aware of these trends, select treatments carefully, and strengthen prevention efforts.

Your daily dose of the clinical news you may have missed.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.

Your daily dose of the clinical news you may have missed.

PODCAST: Family physician Ada Stewart, MD, shares practical strategies for cervical cancer screening and patient communication.

FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.